1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Species | Human |
| Cat.No | ABC-RC104F |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | T Lymphoblast |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Blood |
| Disease | Acute T Cell Leukemia |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Reporter Stable Cell Lines |
| Host Cell | Jurkat |
PD-1 is an immunosuppressive receptor expressed on activated T cells and B cells, playing a critical role in regulating immune responses to tumor antibodies and self-antigens. Interaction between PD-1 on neighboring cells and its ligands PD-L1 or PD-L2 inhibits TCR signaling pathway transduction, as well as TCR-mediated cell proliferation, transcription activation, and cytokine production. Therapeutic antibodies and Fc fusion proteins blocking PD-1/PD-L1 interactions have shown promising application prospects in clinical trials for various cancers. Current methods for evaluating the activity of anti-PD-1 or anti-PD-L1 biological products rely on measuring primary human T cell and functional endpoints such as cell proliferation, cell surface marker expression, interferon-gamma (IFNγ), and interleukin-2 (IL-2) production. Due to reliance on donor primary cells, complex experimental protocols, and substandard reagents, these assays are both labor-intensive and prone to variability. Therefore, these assay methods are challenging to establish in a quality-controlled drug development environment.The Mouse_PD-1 Reporter Jurkat Cell Line is a reporter gene cell line stably expressing the Mouse_PD-1 gene and Luciferase reporter gene. Paired with the Mouse PDL1 aAPC CHO-K1 Cell Line, which stably expresses mouse PD-L1 and a cell surface protein that activates endogenous TCR in an antigen-independent manner. When both cell lines are co-cultured, the interaction between PD-1/PD-L1 inhibits TCR signaling pathway transduction and transcription factor-mediated luciferase expression. Addition of a blocking antibody against PD-1/PD-L1 reverses this inhibition, leading to TCR signaling pathway transduction and transcription factor-mediated luciferase expression, which can be used to assess the efficacy and stability of blocking antibodies against PD-1/PD-L1 interactions and other biological products.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
For research use only